Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Avacta partner to present data on breakthrough technology at Barcelona conference

Avacta’s chief executive, Dr Alastair Smith, said the presentation provided “strong, independent validation of the technical performance of Affimer reagents and is important to our commercialisation of the technology”
Avacta partner to present data on breakthrough technology at Barcelona conference
Affimers are small, engineered proteins, some of which are of human origin

Avacta Group Plc (LON:AVCT) said a partner company will be presenting data on Avacta’s Affimer technology at a leading industry conference in Barcelona, which kicks off Wednesday.

Affimers are small, engineered proteins, some of which are of human origin and some plant-derived. They are capable of binding specific molecular targets, in a similar way to antibodies.

READ: Interest in Affimer technology at record levels, which bodes well for Avacta

The contract research firm Covance will be setting out new information that “highlights the validation of Affimer as a critical reagent in clinical assays when good batch-to-batch stability and reproducible performance are a regulatory requirement”.

Scientists attending the European Bioanalysis Forum will hear the update.

READ: Patient heal thyself - Avacta teams up with Finnish biotech firm to develop system that allows body to create its own drugs

Avacta’s chief executive, Dr Alastair Smith, said the presentation provided “strong, independent validation of the technical performance of Affimer reagents and is important to our commercialisation of the technology”.  

View full AVCT profile View Profile

Avacta Group Plc Timeline

Related Articles

Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
syringe
June 20 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use